Gastroenterology News and Research

RSS

Gastroenterology is the branch of medicine where the digestive system and its disorders are studied.

Low-dose ketamine is safe and effective to treat children with ADNP syndrome, study suggests

Results of a small, but unique research study, led by researchers from the Seaver Autism Center for Research and Treatment at Mount Sinai and published online in Human Genetics and Genomic Advances, suggest that low-dose ketamine is generally safe, well-tolerated and effective to treat clinical symptoms in children diagnosed with ADNP syndrome (also known as Helsmoortel-VanDerAa syndrome), a rare neurodevelopmental disorder caused by mutations in the activity dependent neuroprotective protein (ADNP) gene.

6 Sep 2022

Private equity ownership of physician practices may impose measures to squeeze out more profits, research says

New research reveals private equity firms that acquire physician-owned medical practices appear to be imposing measures to squeeze out more profits.

2 Sep 2022

Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.

1 Sep 2022

Cedars-Sinai investigators create new blood test for early detection of common liver cancer

Cedars-Sinai Cancer investigators have created a blood test that uses a technology made commonly available during the COVID-19 pandemic to detect the most common form of liver cancer - at an early enough stage that cure is possible.

30 Aug 2022

New risk assessment tool predicts mortality for atrial fibrillation patients after completion of TAVR

A large-scale international study led by Mount Sinai has yielded the first risk score that can help predict mortality for patients with atrial fibrillation (AFib) who have undergone a successful transcatheter aortic valve replacement (TAVR) and discharged home.

29 Aug 2022

Three-drug medication effective in preventing recurrent cardiovascular events after a heart attack

A three-drug medication known as a "polypill," developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.

26 Aug 2022

New study investigates a potential treatment for people diagnosed with monkeypox

The team behind the world-leading RECOVERY trial of COVID-19 treatments are leading a new study investigating a potential treatment for people who have been diagnosed with monkeypox.

25 Aug 2022

World's first-in-human research using organoid transplantation yields good results

Tokyo Medical and Dental University (TMDU) research team announced on July 7 that it has succeeded in the world's first clinical transplantation of a "mini organ (also called Organoid)" into a patient with "Ulcerative Colitis (UC)".

22 Aug 2022

UC San Diego Health first to offer new injectable medication to patients with hereditary transthyretin amyloidosis

UC San Diego Health is first in the nation to offer a new injectable medication to patients with nerve damage caused by hereditary transthyretin amyloidosis, a rare disease that can be fatal without management.

18 Aug 2022

New method helps identify which gut microbes most likely contribute to inflammatory diseases

Cedars-Sinai investigators have developed a method to help identify which human gut microbes are most likely to contribute to a slew of inflammatory diseases like obesity, liver disease, inflammatory bowel disease, cancer and some neurological diseases.

17 Aug 2022

Mount Sinai and Regeneron Genetics Center launch a new human genome sequencing research project

Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai have launched a new human genome sequencing research project called the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC), part of the industry-leading, New York-based biotechnology company Regeneron.

12 Aug 2022

Clinicians' reluctance to discuss possible harms of anal sex may be failing a generation of young women

Clinicians' reluctance to discuss possible harms of anal sex is letting down a generation of young women who are unaware of the risks, warn researchers in The BMJ today.

12 Aug 2022

Elevated acetate levels reprogram gut microbiota during alcohol intake

Chronic alcohol use is a major cause of liver damage and death: Approximately 30,000 persons in the United States die annually from alcoholic liver diseases, such as cirrhosis.

11 Aug 2022

How ultraprocessed foods affect gut microbiome and health

Researchers describe the association between the consumption of ultraprocessed foods and chronic medical conditions.

10 Aug 2022

Mount Sinai receives $500,000 SU2C grant to identify therapeutic combinations for KRAS-mutant lung cancers

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.

9 Aug 2022

Discovery could prevent insulin resistance and have significant benefits for people with type 2 diabetes

In a potential game changer for patients with type 2 diabetes, a team of researchers at the Diabetes, Obesity, and Metabolism Institute (DOMI) at the Icahn School of Medicine at Mount Sinai has identified a therapeutic target for the preservation and regeneration of beta cells (β cells) - cells in the pancreas that produce and distribute insulin.

4 Aug 2022

New, non-invasive imaging method may help detect an early indicator of glaucoma

A new, non-invasive ocular imaging method may be able to detect an early indicator of glaucoma in time to prevent disease progression and vision loss, according to a new study from New York Eye and Ear Infirmary of Mount Sinai.

2 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Researchers discover cell signaling pathway responsible for the development of esophageal cancers

Of the roughly 20,000 people in the U.S. diagnosed with esophageal cancer this year, just 4,000 are likely to still be alive in 2027.

28 Jul 2022

Researchers unravel how one gut bacterium influences immunity

From immunity to metabolism to mental health, it seems like the gut microbiome has been linked to every aspect of human health and disease.

27 Jul 2022